Early diagnostics PreCyte develops non-invasive blood-based diagnostic tools using the indicator cell assay platform (iCAP) and machine learning to detect diseases from gene expression responses, presenting a compelling selling point for labs and providers aiming to expand early screening programs for cancer and Alzheimer's.

Targeted cancer screening The company envisions pan-cancer iCAP panels with current focus on lung cancer and Alzheimer's disease, offering opportunities to upsell to healthcare systems and researchers pursuing new lung cancer screening protocols and early detection initiatives.

Funded validation Past and ongoing funding from entities such as NCI and SBIR programs signals credibility and potential for joint grant opportunities, enabling co-development deals and sponsored research arrangements with larger stakeholders.

Boutique partner potential With a small team and niche technology, PreCyte can be an attractive partner for contract research, pilot projects, and early-access programs with larger CROs, biotechs, and analytics firms seeking innovative biomarker detection platforms.

Technology leverage The iCAP platform combines standardized biosensor cells with ML-based disease state prediction, offering a differentiator for collaborations with big players in diagnostic workflows, genomic analysis, and healthcare cloud analytics seeking novel biomarker readouts.